Mustafa Emre DUYGULU, Elanur KARAMAN
European Journal of Geriatrics and Gerontology - 2026;8(1):1-6
Objective: Biomarkers are needed to determine risk groups in the treatment plan of geriatric patients diagnosed with cancer. The Modified Glasgow Prognostic Score (mGPS) is an inflammatory scoring system based on measurements of C-reactive protein and albumin in the blood. In our study, the relationships between the mGPS and clinical parameters and the effect of the mGPS on survival were investigated in older adults with metastatic melanoma. Materials and Methods: Fifty-eight patients aged 65 years and older with a diagnosis of metastatic melanoma were included in the study. The patients were evaluated according to their clinical and pathological features. Overall survival (OS) and progression-free survival (PFS) times and the factors affecting survival were evaluated. Survival relationships by mGPS score were analysed by the Kaplan-Meier method, and prognostic factors for survival were analysed by Cox regression analysis. Results: The mGPS was higher in patients with brain and/or liver metastases and in those with high serum lactate dehydrogenase levels (p = 0.015 and p = 0.003, respectively). A high mGPS was associated with decreased survival time (median PFS for mGPS of 0, 1, and 2 were 9.4, 6.9, and 3.5 months, respectively, p = 0.001; median OS for mGPSs of 0, 1, and 2 were 19.5, 8.2, and 6.4 months, respectively, p = 0.001). In the multivariate analysis, mGPS 2 was found to be an independent risk factor for decreased OS (hazard ratio: 3.26, p = 0.003). Conclusion: A high mGPS was associated with poor survival in metastatic melanoma patients and the mGPS was found to be an independent risk factor for decreased OS.
